PET scan to plan treatment for prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This trial is for men with metastatic castration-resistant prostate cancer who are already scheduled to receive a treatment called Pluvicto. It uses an extra scan (SPECT/CT) to better measure how the treatment reaches the tumors, which could help personalize dosing and improve safety.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have metastatic prostate cancer that no longer responds to hormone therapy
- You are already scheduled to start treatment with Pluvicto
- You are male and at least 18 years old
- You are able to lie flat on a scanning table for the duration of the imaging
- You are willing to sign a consent form
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial will test if a special PET scan (18F-DCFPyL) can help doctors plan your treatment with a radioactive medicine called 177Lu-vipivotide tetraxetan. You are eligible if you already qualify for that standard therapy and have had a prior PSMA PET scan showing at least one active cancer site.
This trial tests a higher dose of a radioactive drug (177Lu-PSMA-617) for men whose prostate cancer has spread and does not produce much of a protein called PSMA on scans. The goal is to see if a stronger dose can work better than the standard dose.
This trial tests whether a special PET scan can predict how well a targeted radiation therapy (177Lu-PSMA-617) works for men with advanced prostate cancer that has stopped responding to hormone therapy. It aims to personalize treatment by checking the radiation dose before therapy starts.
This study uses special scans to see how well the drug Pluvicto is working in men with metastatic prostate cancer. You would have two PET scans, one before starting treatment and one after 12 weeks, to check your cancer's response.
This study tests giving the targeted radiation drug [177Lu]Lu-PSMA again to men whose prostate cancer has started growing after an earlier course of the same treatment. It aims to see if a second round can control the cancer again.
This trial tests a radioactive drug called 177Lu-PSMA-617 to see if it can help men with metastatic castration-resistant prostate cancer that has spread to the bones in a specific pattern (superscan). It's for patients who have already tried hormone therapy and have PSMA-positive tumors.
Hear when a new Metastatic Castration-Resistant Prostate Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.